Dover has entered into a definitive settlement to amass Malema Engineering Corp, a US designer and producer of high-precision, mission-critical flow-measurement and control instruments for the biopharmaceutical, semiconductor and industrial sectors.
Malema’s products will broaden Dover’s biopharma single-use manufacturing offering, which already includes Quattroflow pumps, CPC connectors, and em-tec flowmeters.
Based in Boca Raton, Florida, and with services in San Jose, California, Singapore, South Korea and India, Malema expects to generate roughly US$40 million–45 million in income during the full 12 months 2022.
When the deal closes, Malema will turn into a half of the PSG business unit within Dover’s Pumps & Process Solutions phase.
“We see an incredible long-term progress alternative within the bioprocessing trade pushed by a powerful and growing pipeline of effective novel biologic medication, biosimilars, protein therapies, non-COVID mRNA vaccines, in addition to budding cell & gene therapies,” says PSG’s president Karl Buscher. “Additionally, the rising adoption of more environment friendly single-use manufacturing processes supports a strong outlook for our choices of single-use components to end-customers. We believe that pairing Malema’s know-how with our present portfolio of single-use pumps for biopharma processing will greatly enhance the accuracy and value proposition of our solutions to our clients.”
“We are methodically constructing out our biopharma platform via proactive capability additions, new product improvement, and opportunistic acquisitions of highly-attractive niche part applied sciences,” mentioned Richard Tobin, president and CEO of Dover. “Malema represents a strategic and highly-complementary flow-control and sensing know-how and additional strengthens our sensor portfolio with new proprietary expertise. In เกจวัดแรงดันลมคือ to attractive biopharma purposes, we anticipate sturdy progress in the semiconductor house on the capability expansion and re-shoring tailwinds.”
Share